Get started

MNK

Ready for reverse moveAs Peter Lynch said "buy companies that are hated by public" Touched the bottom of downward channel. Upcoming PDUFA can affect the stock price in a negative way and push it to $1 (or even down below a bit). The company has a huge debt and it is priced as BK company but it has great pipeline and it has all the chances to get a decent deal on opioid case. In such a case it will skyrocket. The issues are the same as they were when the stock price was $80. In case if opioid deal settled company capitalization will be 10 times higher at least. Drivers for further revenue growth: Terlipressin, Stratagraft, iNO. For now, valuation of the company is ridiculous. Be aware it is very high risk game. Kind of binary game.
MLong
by DannyTheBear
1
$MNK A Buy On 56% Of The Float Short$MNK is up 40% this week after positive comments from the company's CFO. With a massive short position in the stock, we think this rally has further room to run. The stock started rallying this week after Chief Financial Officer Bryan Reasons said at the J.P. Morgan Health Care Conference on Monday that the company could pay off its potential 2020 debt maturities, which is a "slightly over" $600 million, in cash. And regarding the dispute with the government over pricing for Acthar, he implied that he was optimistic regarding a favorable outcome, so there was no need to rush to settle. "Right now, we felt like the hearing went really well and we feel good about it," Reasons said, according to a transcript provided by FactSet. "So, we don't feel it's in our best interest to actually initiate the settlements." And regarding the opioid litigations, Chief Executive Mark Trudeau said he was "hopeful" that a resolution can be reached "sooner rather than later." The stock has more than doubled (up 110%) over the past three months, but is still way down 83% off its 52 week high of $27.33 a share. As always, use protective stops and trade with caution. Good luck to all!
M
by InsiderFinancial
$MNK Looks To Be Turning For The Better$MNK has been badly beaten up over the opioid crisis. It's been a favorite of the shorts and they have banked 77% ytd. However, we think judging by the chart, that $MNK has turned the corner and is set to keep climbing. Shorts can help this climb as 55% of the float has been sold short. We could see a massive short covering rally. The latest news is Mallinckrodt (NYSE:MNK) announces positive findings from a large retrospective study of Acthar Gel in the treatment of the respiratory disease symptomatic sarcoidosis. The company says analysis of a test of 302 patients showed that the use of Acthar Gel was associated with improved overall health status in 95% of patients as reported by physicians' assessments, with more than half of patients (54%) seeing improvements in two or more symptoms. Acthar Gel is approved by the FDA for the treatment of symptomatic sarcoidosis. Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with the Washington University School of Medicine and Silence Therapeutics plc. The company was founded in 1867 and is based in Staines-Upon-Thames, the United Kingdom. As always, use protective stops and trade with caution. Good luck to all!
MLong
by InsiderFinancial
2
MNK: DEAT CAT BOUNCE OPPORTUNITYMNK is dead or almost dead. Often times there is a dead cat bounce in stocks like these, as 'everybody' gets the same idea to throw some money at it. This is a high risk scenario but with potentially good risk to reward ratios. Disclaimers : I've clearly said this is high risk. This not advice to trade in securities. I am simply showing what may happen from a perspective of speculative opinion only. Your losses are your own if you enter a trade on this. Kindly sue yourself if you lose your money.
MLong
by Captain_Walker
2
Farewell! My beloved MNK! 3 years ago when I was trading in Wall street, I read a report from Citron research about this company: citronresearch.com I did my own research and confirm my bearish perspective. I remembered so well that day when I called out this short trade to the whole desk, it was around 60.0 spot. "Short MNK!!!!!!!!" That what I said as by then, Citron already made their reputation by the VRX, DDD, GPRO reports, and the market was like whatever names that they are focusing on, will encounter some sort of selling-off in the 1st place! Since then, I always look for short trades on this name every single trading days, even after I left Wall Street, whenever I am asked about individual names, I'll mention MNK and said my target price is ZERO. ( Earning preview @ 2019.08.05 around 10:30-12:00) 3 years passed by, I posted so many short trades on TradingView these years, and today, it dropped another 40% pre-market, It's the best example to show the concept of "It's never too low to sell" Besides sense of achievement, I was kinda sentimental that after all these days, It did made its way to ZERO and it's time for me to move on another name to short lol. Farewell! My beloved MNK!
MEducation
by Trader_Joe_Lee
10
MNK - Promising Opportunity (High Time Value Puts)I think MNK looks interesting at this price. Price has been driven down. Could potentially continue to fall, but in long run, this could be a good potential buy opportunity. Time will tell. The IV% on short dated put options are much higher than normal. I sold a couple 3/2 $15P for .80/contract (3 days till expiration) B.E. (or purchase price if exercised) = $14.20 MNK $16.30 GREEKS D / G: -.0980 / .1606 T / V: -.0188 / .0038 IV: 171.29% (vs. 56.87%) W
M
by JLJ002500
MNK, Another it's never too low to sell story?We've been through DDD,VRX,GPRO to the recent TEVA stories to me MNK is just another. Back to the days I was a proprietary trader, MNK is one of my favorite name as if I don't know what to trade in any given day I tried to short the name. Only if we kept "it's never too low to sell" in mind that we can catch this kind of profit, otherwise we might be stopped out each time when we want to buy the dip. I don't really suggest taking this inside week short as I know it takes gigantic risk appetite to take this trade, but I am more than willing to post in on TradingView to see how it goes afterwards.
M
by Trader_Joe_Lee
1